Nanotechology Provides Hope for Personalized Vaccination for Cancer

出处
期刊:Oncology times [Wolters Kluwer]
卷期号:42 (20): 34-34 被引量:1
标识
DOI:10.1097/01.cot.0000721364.82026.d4
摘要

vaccination: vaccinationOne of the key challenges in developing effective targeted cancer treatments is the heterogeneity of the cancer cells themselves. This variation makes it difficult for the immune system to recognize, respond to, and actively fight against tumors. Now, however, new advances in nanotechnology are making it possible to deliver targeted, personalized “vaccines” to treat cancer. A new study, published in Science Advances, demonstrates the use of charged nanoscale metal-organic frameworks for generating free radicals using X-rays within tumor tissue to kill cancer cells directly (2020; doi: 10.1126/sciadv.abb5223). Furthermore, the same frameworks can be used for delivering immune signaling molecules known as PAMPs to activate the immune response against tumor cells. By combining these two approaches into one easily administered “vaccine,” this new technology may provide the key to better local and systemic treatment of difficult-to-treat cancers. Study Details In a collaboration between the Lin Group in the University of Chicago Department of Chemistry and the Weichselbaum Lab at University of Chicago Medicine, the research team combined expertise from inorganic chemistry and cancer biology to tackle the challenging problem of properly targeting and activating an innate immune response against cancer. This work leveraged the unique properties of nanoscale metal-organic frameworks (nMOFs)—nanoscale structures built of repeating units in a lattice formation that are capable of infiltrating tumors. These nMOFs can be irradiated with X-rays to generate high concentrations of free oxygen radicals, killing the cancer cells directly and producing antigens and inflammatory molecules that help the immune system recognize and clear cancerous cells, much like a vaccine. Their lattice-like structure also makes nMOFs ideal transporters for delivering anti-cancer drugs directly to tumors. Thus far, however, it has been difficult to activate innate and adaptive immune responses necessary for eliminating cancerous tumors. In this new study, the researchers fine-tuned their approach even further. This time, they generated a new type of nMOF structure that could be loaded with drugs known as pathogen-associated molecular patterns, or PAMPs. Now, when the nMOFs were applied to cancerous tumors, irradiating the tissue had a double effect: it triggered the nMOFs to kill local cancer cells to produce antigens against the tumor and released the PAMPs, which then triggered a much stronger activation of the immune response to the tumor antigens. This one-two punch was capable of killing both colon and pancreatic cancer cells with high efficacy, even in tumor models that are highly resistant to other kinds of immunotherapy. In further experiments with mice, the investigators saw they could extend the effects of the nMOFs even to distant tumors with the application of checkpoint inhibitors, providing new hope for treating cancer both locally and systemically with this approach. “By including PAMP delivery with the nMOFs, this is the first time we were able to really enhance the immune response to the antigens,” said senior author Wenbin Lin, PhD, the James Franck Professor of Chemistry and a primary investigator of tumor immunology at the Ludwig Cancer Center at UChicago. “This is entirely different from all of our previous studies because we've shown that the nMOFs plus PAMPs can impact all of the aspects required for activating the immune system. We can use this nanoformulation to enable personalized cancer vaccinations that will work on any patient, because this strategy will not be subject to the heterogeneity we see among different patients.” The effects of the treatment were so pronounced that the researchers are eager to bring the technology to clinical trials, where other versions of the nMOF technology are already being tested, with promising results thus far. “The brilliance of this system is twofold,” said co-author Ralph Weichselbaum, MD, the Daniel K. Ludwig Distinguished Service Professor of Radiation and Cellular Oncology and Chair of the Department of Radiation and Cellular Oncology at UChicago. “First, it can improve local tumor control by increasing the killing power of X-rays. Second, while there has been interest in using radiation to stimulate the immune response to fight cancer, it has turned out to be harder than we thought. In this case, the nMOFs are able to activate the innate and adaptive immune systems, which makes this technology very promising for treating cancer in the clinic.” Already looking ahead to next steps, the investigators are working on refining the technology. “We're refining the design of the nMOF and its delivery of the PAMPs, in preparation for testing it in humans,” said Lin. “We're really working on zooming in on the best formulation so we can get this into clinical trials, hopefully in the next two to three years, or even sooner.” The team credits the interdisciplinary and collaborative nature of UChicago and University of Chicago Medicine's Hyde Park campus for creating a space where chemistry and cancer biology have combined to produce such a promising potential therapy, as well as the support they've received from Ludwig Cancer Research along the way. “From the conception of this project and getting it funded to starting with clinical trials where we're able to test the technology in clinical trials and get real patient data, this work has all been done right here at UChicago,” said Weichselbaum. “We really are going from discovering something in the lab to testing it at the bedside.”

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
no1isme完成签到 ,获得积分10
2秒前
FengQY完成签到 ,获得积分10
2秒前
吴旭东完成签到,获得积分10
3秒前
某某完成签到,获得积分10
4秒前
王12完成签到,获得积分10
5秒前
seemon完成签到 ,获得积分10
5秒前
6秒前
笑对人生完成签到 ,获得积分10
7秒前
7秒前
打打的应助被等待幼荷采纳,获得10
7秒前
mongmong完成签到 ,获得积分10
8秒前
要减肥的湘云完成签到,获得积分10
8秒前
木木完成签到,获得积分10
8秒前
生物科研小白完成签到 ,获得积分10
9秒前
ange完成签到,获得积分10
10秒前
青桔完成签到,获得积分10
11秒前
lz完成签到,获得积分10
11秒前
koi完成签到,获得积分10
11秒前
科研废柴完成签到 ,获得积分10
12秒前
惜缘完成签到 ,获得积分10
12秒前
YY完成签到,获得积分10
12秒前
GraysonG完成签到 ,获得积分10
12秒前
小暴完成签到,获得积分10
13秒前
沈澜完成签到 ,获得积分10
14秒前
你好完成签到 ,获得积分10
15秒前
16秒前
chenyunxia完成签到,获得积分10
16秒前
一心完成签到,获得积分10
17秒前
崔文浩完成签到,获得积分10
17秒前
单身的绮烟完成签到 ,获得积分10
18秒前
飘逸的小天鹅完成签到,获得积分10
19秒前
zuijiasunyou完成签到,获得积分10
20秒前
学术小白完成签到,获得积分10
20秒前
山岚完成签到 ,获得积分10
20秒前
wangyujie完成签到,获得积分10
21秒前
Yingqian_Zhang完成签到 ,获得积分10
21秒前
511完成签到 ,获得积分0
21秒前
束玲玲完成签到,获得积分10
22秒前
韭黄完成签到,获得积分10
22秒前
ming2026的应助被崔文浩采纳,获得20
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719828
捐赠科研通 7748795
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428